UCB Pharma
UCB Pharma’s bimekizumab improves skin clearance over Humira in plaque psoriasis
November 3, 2020Manufacturing and Production, Research and Development UCB Pharma, bimekizumab, pharma
In recent Phase 3 study data presented European Academy of Dermatology and Venereology Congress last weekend, UCB Pharma reported that …
UCB’s bimekizumab meets primary and secondary endpoints, beating Janssen’s Stelara in chronic plaque psoriasis
October 17, 2019Research and Development Stelara, UCB Pharma, bimekizumab, pharma, plaque psoriasis
UCB Pharma has announced new data from the first of three Phase 3 studies investigating the efficacy of its IL-17A …
New Phase 3 data confirms safety and efficacy of UCB’s Cimzia in plaque and psoriatic arthritis
April 30, 2019Manufacturing and Production, Research and Development Cimzia, UCB Pharma, pharma, plaque psoriasis, psoriasis
New Phase 3 data has been released by UCB Pharma on the safety of Cimzia (certolizumab pegol) in the treatment …
NICE recommends UCB’s Cimzia in severe plaque psoriasis
April 18, 2019Sales and Marketing Cimzia, NICE, UCB Pharma, UK, pharma, plaque psoriasis, psoriasis
NICE has announced its decision to recommend UCB Pharma’s Cimzia (certolizumab pegol) for use on the NHS in England in …
FDA green lights Amgen and UCB’s Evenity in postmenopausal osteoporosis patients
April 10, 2019Research and Development, Sales and Marketing Amgen, Evenity, FDA, UCB Pharma, osteoporosis, pharma
The FDA has decided to approve Amgen and UCB Pharma’s Evenity (romosozumab-aqqg) for the treatment of postmenopausal osteoporosis patients at …
UCB teams up with charity to beat treatment-resistant epilepsy in $2.5m partnership
February 11, 2019Research and Development, Sales and Marketing Epilepsy Society, UCB Pharma, epilepsy, pharma
Belgian firm UCB Pharma has announced a new partnership with the charity Epilepsy Society which will see the pair invest …
Amgen and UCB’s Evenity approved in Japan for osteoporosis
January 9, 2019Research and Development, Sales and Marketing Amgen, Japan, UCB Pharma, osteoporosis, pharma
Amgen has revealed that its bone-forming monoclonal antibody Evenity (romosozumab), developed in partnership with UCB Pharma, has been awarded approval …
UCB targets regulatory filing for its osteoporosis drug in 2016
March 3, 2016Medical Communications, Research and Development, Sales and Marketing Romosozumab, UCB Pharma, osteoporosis
Belgian drug company UCB says it is looking at a regulatory filing for its trial drug romosozumab to treat osteoporosis …
New epilepsy drug launches in UK
February 29, 2016Medical Communications, Research and Development, Sales and Marketing Briviact, UCB Pharma, epilepsy
UCB Pharma’s Briviact (brivaracetam) has been authorised as an add-on treatment for partial onset seizures (POS), with or without secondary …
AbbVie VP joins UCB Pharma
January 25, 2016Manufacturing and Production, Research and Development, Sales and Marketing Pascale Richetta, UCB, UCB Pharma
Pascale Richetta will join the UCB as its new head of the bone therapy patient value unit as from February …
